Clinical Trials Browser

Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Neoplasms, Squamous Cell

NCT05119998 2023-08-18

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Phase 1 Completed

48 enrolled

Other solid neoplasm

Solid Tumor

NCT05976568 2023-08-04

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Phase 2/3 Not yet recruiting

668 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05026593 2023-07-19

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Phase 1 Completed

60 enrolled

Thoracic

SCLC

NCT04672356 2023-06-22

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Phase 1 Completed

19 enrolled

Thoracic

Advanced Lung Cancer

NCT04672369 2023-06-22

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Phase 1 Completed

42 enrolled

Thoracic

Advanced Lung Cancer

NCT05653180 2023-04-03

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Unknown

20 enrolled

Gastrointestinal

Advanced Biliary Tract Cancer

NCT03745170 2023-03-01

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Phase 3 Completed

650 enrolled

Gastrointestinal

Stomach Neoplasms

NCT03150875 2023-02-28

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

Phase 3 Completed

290 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03545971 2023-02-28

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Phase 1 Completed

53 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT03629925 2023-02-28

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Phase 3 Completed

357 enrolled 14 charts

Thoracic

Squamous NSCLC

NCT03607539 2023-02-27

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Phase 3 Completed

397 enrolled 15 charts

Thoracic

Lung Neoplasms

NCT04177290 2023-02-27

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

Phase 1 Completed

48 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05118334 2023-02-23

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

Phase 1 Completed

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03758001 2023-02-22

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

Phase 1 Completed

38 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05572463 2022-11-18

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Phase 1/2 Withdrawn

Dermatologic

Melanoma, Neoplasms

NCT02937116 2022-10-14

First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors

Phase 1 Completed

233 enrolled 30 charts

Tumor-Agnostic

Neoplasms

NCT04861948 2022-10-04

IBI188 Combination Therapy in Solid Tumors

Phase 1 Terminated

9 enrolled

SarcomaThoracic

Adenocarcinoma of Lung, Osteosarcoma

NCT05280626 2022-03-15

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Phase 2 Not yet recruiting

100 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04427774 2021-07-20

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Phase 1 Terminated

8 enrolled

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT03568539 2021-06-01

IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

Phase 1 Completed

39 enrolled 16 charts

Advanced/Metastatic Solid Malignancies

NCT03116152 2021-02-03

Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment

Phase 2 Completed

190 enrolled 14 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03794440 2021-01-22

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Phase 2/3 Unknown

595 enrolled

Gastrointestinal

Carcinoma, Hepatocellular